Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy

Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy

US Patent 12258421 · Granted Mar 25, 2025

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Lym-1 and Lym-2 antibody compositions and improved car constructs2023
Lym-1 and Lym-2 antibody compositions and improved car constructs2023
Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy2022
Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy2022
Car t-cell therapy directed to LHR for the treatment of solid tumors2021
Car t-cell therapy directed to LHR for the treatment of solid tumors2021
CD20 scFv-ELPs methods and therapeutics2021
CD20 scFv-ELPs methods and therapeutics2021
Lym-1 and Lym-2 targeted CAR cell immunotherapy2020
OX40L fusion protein for the immunotherapy of tumors of veterinary animals2019
OX40L fusion protein for the immunotherapy of tumors of veterinary animals2019
Human myeloid derived suppressor cell cancer markers2017